The impact of the intestinal microbiota and the mucosal permeability on three different antibiotic drugs
| Autor: | Michele Pier Luca Guarino, Giovanni Palombo, Mario Merone, Carlotta Terradura, Vincenzo Piemonte, Michele Cicala, Annamaria Altomare, Luca Bacco, Manuele Gori, Lorenza Putignani, Federica Del Chierico |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Drug bioavailability
Intestinal microbiota Urinary system Pharmaceutical Science 02 engineering and technology 030226 pharmacology & pharmacy Permeability Feces 03 medical and health sciences 0302 clinical medicine RNA Ribosomal 16S medicine Gut barrier function Humans Intestinal Mucosa Respiratory system Irritable bowel syndrome Ussing chamber biology business.industry Genitourinary system Human microbiome 021001 nanoscience & nanotechnology medicine.disease biology.organism_classification Anti-Bacterial Agents Gastrointestinal Microbiome Bioavailability Pharmaceutical Preparations Immunology 0210 nano-technology business Compartmental models Bacteria |
| Zdroj: | European journal of pharmaceutical sciences 164 (2021). doi:10.1016/j.ejps.2021.105869 info:cnr-pdr/source/autori:Palombo, Giovanni; Merone, Mario; Altomare, Annamaria; Gori, Manuele; Terradura, Carlotta; Bacco, Luca; Del Chierico, Federica; Putignani, Lorenza; Cicala, Michele; Guarino, Michele Pier Luca; Piemonte, Vincenzo/titolo:The impact of the intestinal microbiota and the mucosal permeability on three different antibiotic drugs/doi:10.1016%2Fj.ejps.2021.105869/rivista:European journal of pharmaceutical sciences/anno:2021/pagina_da:/pagina_a:/intervallo_pagine:/volume:164 |
| Popis: | BackgroundThe totality of bacteria, protozoa, viruses and fungi that lives in the human body is called microbiota. Human microbiota specifically colonizes the skin, the respiratory and urinary tract, the urogenital tract and the gastrointestinal system. This study focuses on the intestinal microbiota to explore the drug-microbiota relationship and, therefore, how the drug bioavailability changes in relation to the microbiota biodiversity to identify more personalized therapies, with the minimum risk of side effects. MethodsTo achieve this goal, we developed a new mathematical model with two compartments, the intestine and the blood, which takes into account the colonic mucosal permeability variation - measured by Ussing chamber system on human colonic mucosal biopsies - and the fecal microbiota composition, determined through microbiota 16S rRNA sequencing analysis. Both of the clinical parameters were evaluated in a group of Irritable Bowel Syndrome patients compared to a group of healthy controls. Key ResultsThe results show that plasma drug concentration increases as bacterial concentration decreases, while it decreases as intestinal length decreases too. ConclusionsThe study provides interesting data since in literature there are not yet mathematical models with these features, in which the importance of intestinal microbiota, the "forgotten organ", is considered both for the subject health state and in the nutrients and drugs metabolism. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|